Efficacy of neoadjuvant pembrolizumab combined with paclitaxel and cisplatin in locally advanced oropharyngeal and hypopharyngeal squamous cell carcinoma: a retrospective study.

ABSTRACT:

Objective

This retrospective study aims to evaluate the efficacy and safety of pembrolizumab combined with paclitaxel and cisplatin (ICI+TP) in the treatment of locally advanced oropharyngeal and hypopharyngeal squamous cell carcinoma (OPHSCC).

Methods

Patients with locally advanced OPHSCC who received ICI+TP, cetuximab with paclitaxel-cisplatin (CET+TP), or paclitaxel-cisplatin alone (TP) were reviewed. Radiographic and pathological response rates, transoral surgery rates, and survival outcomes were assessed.

Results

A total of 83 patients were enrolled in this study, with 23 subjected to ICI+TP, 31 to CET+TP, and 29 to TP. Compared with TP, ICI+TP yielded superior clinical outcomes: a higher objective response rate (ORR) (91.3% vs. 55.2%, p<0.05), greater tra

SUBMITTER: Tang S 

PROVIDER: S-EPMC12678248 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature